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Abstract
Background: The local and systemic activation and regulation of the immune system by malignant cells during
carcinogenesis is highly complex with involvement of the innate and acquired immune system. Despite the fact
that malignant cells do have antigenic properties their immunogenic effects are minor suggesting tumor induced
mechanisms to circumvent cancer immunosurveillance. The aim of this study is the analysis of tumor immune
escape mechanisms in a colorectal liver metastases mouse model at different points in time during tumor growth.
Methods: CT26.WT murine colon carcinoma cells were injected intraportally in Balb/c mice after median
laparotomy using a standardized injection technique. Metastatic tumor growth in the liver was examined by
standard histological procedures at defined points in time during metastatic growth. Liver tissue with metastases
was additionally analyzed for cytokines, T cell markers and Fas/Fas-L expression using immunohistochemistry,
immunofluorescence and RT-PCR. Comparisons were performed by analysis of variance or paired and unpaired t
test when appropriate.
Results: Intraportal injection of colon carcinoma cells resulted in a gradual and time dependent metastatic growth.
T cells of regulatory phenotype (CD4+CD25+Foxp3+) which might play a role in protumoral immune response
were found to infiltrate peritumoral tissue increasingly during carcinogenesis. Expression of cytokines IL-10, TGF-b
and TNF-a were increased during tumor growth whereas IFN-g showed a decrease of the expression from day 10
on following an initial increase. Moreover, liver metastases of murine colon carcinoma show an up-regulation of
FAS-L on tumor cell surface with a decreased expression of FAS from day 10 on. CD8+ T cells express FAS and
show an increased rate of apoptosis at perimetastatic location.
Conclusions: This study describes cellular and macromolecular changes contributing to immunological escape
mechanisms during metastatic growth in a colorectal liver metastases mouse model simulating the situation in
human cancer.
Background
Colorectal carcinoma is the third most common cause
of cancer-related deaths worldwide. Although great pro-
ceedings have been made in diagnosis and treatment,
still 40-50% of colorectal cancer patients die of the dis-
ease within five years of diagnosis [1]. Formation of
hepatic metastases in colorectal cancer is associated
with poor prognosis, resulting in the death of more than
80% of patients over the long-term [2]. Surgery is the
primary treatment option for isolated metastases, but
only 20% to 25% of patients displaying hepatic metas-
tases are suitable for resection and recurrence after sur-
gical therapy is frequent [3]. Therefore, the development
of new treatment modalities for liver metastases of col-
orectal cancer is urgently needed. Particularly with
regard to therapeutic modification of the immune sys-
tem, understanding of tumor-specific immunological
responses and mechanisms leading to induction or sup-
pression of the immune system are required.
The local and systemic activation and regulation of
the immune system by malignant cells during carcino-
genesis is highly complex with involvement of the innate
and acquired immune system [4]. Despite the fact that
malignant cells do have antigenic properties their
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immunogenic effects are minor. The causes of a weak
immune response to malignant cells are multifarious
and subsumed in the term “tumor immune escape”.
Important single mechanisms of the immune escape are
down regulation of MHC-class I complex, loss of co-sti-
mulatory surface antigens, decreased expression of
apoptosis inducing death receptors (e.g. Fas/TRAIL
receptor) on malignant cell, and loss of tumor infiltrat-
ing cytotoxic T cells by tumor induced apoptosis [5]. An
additional, very important aspect of the “tumor immune
escape” during carcinogenesis is a significant disturbed
cellular immune response [6]. Regarding an effective cel-
lular immune response the presence or absence of effec-
tor and regulatory T-cells is essential. According to the
cytokine profile CD4+ T-cells can be divided in Th1 (T-
helper 1)-cells, characterised by the secretion of IFN-g,
in Th2 (T-helper 2)-cells, characterised by the secretion
of IL-4/IL-5 and in so called Tr1 cells, characterized by
the secretion of IL-10. Furthermore TGF-b secretion is
the main characteristic of Th3 cells [7,8]. Basically, Th1-
cells activate cytotoxic CD8+ T-cells thus causing an
antitumoral effect whereas Th2/Th3/Tr1-cells boost the
tumor progression by secretion of the above mentioned
cytokines. The change of a Th-1 cell mediated cytokine
profile to a profile typical for Th2/Th3/Tr1-cells is
called “Th-1/Th-2 shift” and is considered a major cause
of an ineffective cellular immune response during carci-
nogenesis [9]. Furthermore, regulatory CD4+CD25+ T-
cells (Tregs) which express the transcriptional repressor
gene Foxp3 and emerge as mature T cells from the thy-
mus, are increasingly under consideration in regard of
the ineffectiveness of the cellular immune response to
malignant cells [10-12]. Tregs play a critical role in
maintaining tolerance to self antigen and in preventing
autoimmunity [13]. Inducible Tregs are generated in the
periphery in response to pathogens and self antigens
[7,14]. However, the induction or activation of Tregs by
pathogens may be one strategy to subvert protective
immunity whereas depletion of CD4+CD25+ Tregs
enhances survival during certain infections [15]. Under
certain conditions, typically following exposure to IL-10
or TGF-b, dendritic cells within the tumor microenvir-
onment and cancer cells can initiate the development of
Tregs limiting effector responses by inhibition of cyto-
toxic T-cells thus impairing anti tumor immunity
[16,17]. In conclusion, TGF-b and IL-10 expression is
intimately implicated in tumor development and contri-
butes to many features of tumor cell biology.
In this study we used an intraportal liver metastases
animal model with CT26.WT colon cancer cells for the
time-dependent analysis of immunological tumor escape
mechanisms during carcinogenesis considering the
above mentioned cytokine and cellular interactions.
Methods
Animals
Female Balb/c mice, 6-8 weeks of age, were purchased
from Harlan-Winkelmann (Borchem, Germany). Animals
were maintained under conventional housing conditions
and under specific pathogen-free conditions. Regular
screenings for the presence of murine pathogens (such as
Mycoplasma pulmonis, Streptococcus pneumoniae, and
Helicobacter spp.) were performed. All mice were fed a
commercial diet, given water ad libitum, and subjected to
an equal 12-hour light/dark cycle in accordance with
institutional guidelines. Housing and all procedures invol-
ving animals were performed according to protocols
approved by the University’s animal care committee and
in compliance with the guidelines on animal welfare of
the National Committee for Animal Experiments.
Cell line
CT26 is an N-nitroso-N-methylurethane-(NNMU)
induced, undifferentiated murine colon carcinoma cell
line, which was cloned to generate the cell line designated
CT26.WT (LGC promochem, Germany). This cell line is
tumorigenic and induces colon carcinoma in rodents
[18]. CT26.WT cells were propagated and subcultured
according to the distributor’s protocol. The cultures were
routinely tested for mycoplasma contamination to ensure
that only negative cells were used.
Surgical procedure
The surgical procedure of intraportal tumor cell injec-
tion has already been described extensively [19]. 1 × 105
tumor cells in 100 μl PBS were injected into the portal
vein using a 32G needle. In all control group animals a
laparotomy and an intraportal injection of 100 μl PBS
solution without tumor cells was performed (n = 3).
Mice were sacrificed at 5, 10, 15, and 20 days after
injection (n = 7 mice per group) or earlier if tumor
related cachexy or hepatic failure with tumor related
ascites occurred. Control group animals were sacrificed
on day 5 following PBS injection. Liver and lung tissues
of all animals were collected and subjected to histologi-
cal examination. Liver metastases were further examined
by immunohistochemistry, Real Time PCR, and TUNEL
assay. All surgical procedures administered to the ani-
mals were in accordance with institutional guidelines.
Tumor volumes were calculated by measurements of
the short and long axis of the mass of the prominent
metastasis, where V = π/6 × a2 × b (a: short axis of the
tumor, b: long axis of the tumor).
Immunohistochemistry/Immunofluorescence
About half of the complete liver tissue was fixed in 4%
buffered formalin for histological examination and
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PCR-analysis. Paraffin sections were evaluated using
hematoxylin and eosin. The rest of the liver tissue was
either snap-frozen and stored at -80°C for RNA extrac-
tion and Real Time PCR analysis or fixed in acetone for
Cryostat sections.
Monoclonal antibodies (mAb) were purchased as fol-
lows: anti-CD4-mAb (MCA 1767), anti-CD8-mAb
(MCA 609G), anti-CD25-mAb (14-0251), anti-Foxp3-
mAb (14-5773) from eBioscience (San Diego, CA, USA),
anti-FAS-L-mAb (ab21233) and anti-FAS-mAb (321-335
Cat. No. PC69) from Calbiochem (Darmstadt,
Germany). Cy3 conjugated anti-CD4-mAb and anti-
CD8-mAb were purchased from Linaris (Wertheim,
Germany). Isotype-matched mAbs or purified IgG1
(MCA1211, Serotec, Oxford, England) and controls for
residual endogenous peroxidase activity were included
in each experiment.
The analysis of single staining was performed for CD4,
Foxp3, CD8, CD25, FAS, and FAS-L. Immunohisto-
chemical double staining was carried out for CD4 and
CD8 following standard staining procedures. For immu-
nohistochemical double staining, antibodies bound dur-
ing the first staining step were eluted using LIN-Block
(RAG0149LK) (Linaris, Wertheim, Germany) according
to the manufacturer’s instructions, and the slides were
subsequently incubated with the second primary mAb
diluted in TBS plus 0.5% BSA for 20 min at 37°C fol-
lowed by AP-conjugated secondary antibody and devel-
opment with Vector Blue (SK-5300) (Linaris) for 30 min
and counterstaining with hemalaun for 1 minute.
The sequential immunofluorescence double staining
(coexpression) was detected with Foxp3+ and CD4+ and
FAS+ with CD8+ cells. The slides were incubated with
the primary antibody or control antibody diluted in TBS
plus 0.5% bovine serum albumin (BSA) overnight at 4°C
in a humidified chamber and with secondary FITC-con-
jugated (fluorescein isothiocyanate) antibody for 30 min-
utes at room temperature in a humidified chamber. The
slides were blocked with 10% normal rat serum diluted
in TBS and incubated with the Cy3 conjugated primary
antibody diluted in TBS plus 0.5% BSA overnight at 4°C
in a humidified chamber. Slides were counterstained
with DAPI (4’,6-diamidino-2-phenylindole) if necessary
(Sigma-Aldrich, Steinheim, Germany).
The quantification of each immunohistochemical
staining was done by cell counting in six individual
representative high power fields (× 400). Likewise, the
evaluation of immunofluorescent double staining was
performed by counting CD4+ or CD8+ cells in six high
power fields (×400) together with Foxp3+ or FAS+ cells
in cryostat sections. The proportion of Foxp3 positivity
in counted CD4+ and the proportion of FAS positivity
in counted CD8+ cells were expressed in percentages.
The result of the staining was expressed in percentages
(%) positivity. Results were examined by two blinded
and unbiased colleagues experienced in gastrointestinal
pathology and histology.
RNA extraction
RNA was extracted using an RNA extraction kit (Qia-
gen, Hilden, Germany) from at least 10 mg of homoge-
nized tumor tissue. After homogenization DEPC-75%
ethanol was added to the lysate to provide ideal binding
conditions. The lysate was then loaded onto the RNeasy
silica membrane ("RNeasy Mini spin column”). After
binding of RNA all contaminants, including genomic
DNA, were efficiently washed out. Pure, concentrated
RNA was eluted in water and stored at -70°C until
further analyses. The amount of total RNA was deter-
mined by measuring absorbance at 260 nm. The purity
of the total RNA was established by confirming that the
260 nm: 280 nm ratio was within a 1.8-2.0 range, indi-
cating that the RNA preparations were free of protein
contaminants.
RT-PCR for cytokine genes in metastatic tumor specimens
mRNA expression of representative surface molecules
and cytokines (CD4, CD8, CD25, Foxp3, IL-10, TGF-b,
TNF-a, IFN-g, FAS, and FAS-L) was analyzed in meta-
static tumor specimens by Real Time PCR. Experiments
were done 4-6 times per animal. RNA was extracted as
described above. cDNA was prepared using 2 μg of
heat-denatured RNA. Primer sets from Quiagen (Hilden,
Germany) were used for analysis. Optimum primer con-
centration was determined by titration. Real Time quan-
titative PCR was performed in a two-step RT-PCR using
SYBR-Green PCR Master Mix (PE Biosystems, Foster
City, CA) with 100 ng cDNA and 300 nM of primers in
a total reaction volume of 50 μl. PCR thermal cycling
conditions were as follows: 95°C for 10 min, followed by
40 cycles of 95°C for 15 sec and 60°C for 60 sec. Gene
specific products were continuously measured by an
ABI PRISM 7700 sequence detector (Applied Biosys-
tems, Foster City, CA) and relative quantification was
performed following the manufacturer’s instructions.
In situ detection of apoptosis
To identify cells with fragmented DNA we used a noniso-
topic DNAend-labeling in situ technique, employing
digoxigenin-dNTP and terminal transferase (ApopTag®
Fluorescein in Situ Apoptosis Kit, Chemicon, Planegg-
Muenchen, Germany). Briefly, sections were post-fixed
and equilibrated in terminal transferase buffer before the
addition of reaction buffer containing digoxigenin-dNTP
oligonucleotide. The digoxigenin-dNTP-containing oligo-
nucleotide extensions were detected by anti-digoxigenin-
fluorescein conjugate diluted in a blocking agent, followed
by blocking with 10% normal rat serum diluted in TBS
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(DAKO) and incubated with the Cy3 conjugated primary
antibody anti-CD8-mAb diluted in TBS plus 0.5% BSA
overnight at 4°C in a humidified chamber. The sections
were washed and covered with Polyvinyl-alcohol mount-
ing medium (DABCO) (Sigma-Aldrich) and analyzed
using a Zeiss camera (Jena, Germany). Photographed
Images using the Metamorph software (Visitron Systems,
Puchheim, Germany) package were imported into Micro-
soft Office Picture Manager. For negative controls, sec-
tions were incubated with TUNEL reaction mixture
without TdT. For positive controls, sections of female
mammary gland were used.
The apoptotic index (AI) was defined as the ratio of
TUNEL-positive infiltrated cells to all counted infiltrated
cells × 100. For each group, the number of stained cells
was counted in at least ten 400 × high-power fields.
Cells were defined as apoptotic if the whole nuclear area
of the cell labelled was positive.
Statistical analysis
Results were expressed as mean ± SD. Each of the above
mentioned studies was performed in seven mice per
group. Comparisons were performed by analysis of var-
iance or paired and unpaired t test when appropriate.
Bonferroni’s correction for multiple comparisons was
used to determine the level of significance. p < 0.05 was
considered significant.
Results
Induction of liver metastases by intraportal injection of
CT26.WT colon carcinoma cells
The injection of 1 × 105 CT26.WT cells in 100 μl PBS-
solution resulted in development of hepatic metastases
in all animals. There was a continuous increase in
tumor volume overtime (day 5: 8.4 ± 2 mm3, day 10:
150.7 ± 32 mm3, day 15: 435.4 ± 37 mm3, day 20 680.3
± 41 mm3). Therefore, the injection of 1 × 105 CT26.
WT cells was used for this study. None of the animals
showed pulmonary metastases.
Analysis of T cell infiltration at early and late tumor
stages
Real Time PCR analysis following intraportal injection
of 1 × 105 CT26.WT cells (n = 7 at each time point)
showed significantly higher gene expression level of spe-
cific T cell markers during metastatic growth. A signifi-
cant increase of the expression of CD4, Foxp3 and CD8
could be shown at all points of time compared to the
previous time segment. Additionally, the expression of
CD4 and CD8 at day 5 was already significantly
increased compared to control tissue. The expression of
CD25 showed a significant increase from day 5 to day
10 and from day 15 to day 20. Relative quantification
value, fold difference, is expressed as 2-ΔΔCt (Figure 1a).
These findings were immunohistologically confirmed
showing an expression pattern according to the
increased gene expression of CD4, Foxp3, CD8, and
CD25 during formation of liver metastases. Immunohis-
tologically increasing numbers of Foxp3+ T cells as well
as CD4, CD25, and CD8 were detected during carcino-
genesis (Figure 1b). Especially the number of CD4+ T
cells increased over proportionally on day 20 post injec-
tionem (Figure 2a). Using immunofluorescence Foxp3+
expressing cells were identified as CD4+ phenotype
which were increased at day 20 compared to day 10
(Figure 2b).
Cytokine expression
Following injection of 1 × 105 CT26.WT cells Real Time
PCR analysis showed significantly increasing gene
expression of IL-10 from day 10 to day 20. The expres-
sion of TGF-b was significantly increased on day 10 and
15 compared to the previous point of time, whereas
TNF-a showed a significant increase in expression only
until day 10. From this time on no significant changes
occurred with TNF-a. In contrast, IFN-g gene expres-
sion increased significantly until day 10. From day 10
on, however, a significant decrease of expression could
be observed until day 20 (Figure 3).
Analysis of FAS/FAS-L expression on tumor cells during
metastatic growth
In Real Time PCR analysis, down regulation of FAS
gene expression in metastatic liver tissue could be
detected from day 10 on (p < 0.05 day 10 to day 15) fol-
lowing an initial increase in FAS gene expression at day
5 and 10. FAS-L expression was increased during tumor
development (p < 0.05, day 10 compared to day 15 and
day 20 respectively, Asterisk) (Figure 4a). Immunohisto-
logically FAS-L expression was morphologically attribu-
ted to the tumor cells in liver metastases at late tumor
stages (p < 0.05, day 10 compared to day 15, day 20 and
normal tissue, respectively, Asterisk; Figure 4b, 5a).
Additionally the immunohistological detection of FAS
receptor in liver metastases showed a significant
decrease from day 10 to day 15 following an initial
increase in expression (Fig 4b, 5b). The expression of
FAS and FAS-L by tumor cells was confirmed by posi-
tive control staining of the tumor cell line CT.26 WT.
FAS expression was observed predominantly on CD8+
T cells infiltrating the perimetastatic margin: CD8+/FAS
day 10: 12 ± 4.9%, day 15: 15 ± 5.4%, day 20: 21 ± 4.7%
(day 20 shown in Figure 6a). TUNEL assay confirmed
apoptotic events in these perimetastatic areas and
showed an increased rate of apoptotic CD8+ cells during
tumor growth: CD8+/TUNEL day 10: 5.6 ± 2.9%, day
15: 13 ± 4.7%, day 20: 20 ± 3.4% (day 20 shown in
Figure 6b).
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Discussion
Based on the hypothesis of the immunogenic effect of
malignant transformed cells, firstly announced in 1957 by
Sir Frank MacFarlane Burnet, lymphocytes have a central
role in cancer immunosurveillance [20]. Nowadays this
hypothesis is proven although the interaction between
malignant tumors and the immune system is much more
complex than Mr Burnet thought more than fifty years
ago. Increasing knowledge of the interplay between
malignant cells and the innate and adaptive immune sys-
tem is the basis for the development of modern immu-
notherapeutic strategies. These strategies, however, need
to be tested preclinically in reliable animal models.
In this study we describe a colorectal liver metas-
tases animal model showing tumor growth in an
immunocompetent mouse. In such a model tumor
induced immune responses similar to the situation in
human beings can be analysed at different points of
time during carcinogenesis. In this regard such a model
can be an important tool for further immunotherapeutic
intervention studies.
CT26.WT, which has been used in this study, is a
common murine colon cancer cell line, which has been
used in several studies to investigate the mechanisms of
tumor stromal interactions and anti-tumor immune
responses [21,22]. Numerous animal models have been
developed to gain detailed information on initiation,
promotion, and progression of colorectal liver metas-
tases. The morphology, biochemical alterations, and bio-
logical behaviour of the malignant disease should be,
Figure 1 (a) Real Time PCR: Significantly increasing gene expression of CD4, Foxp3, CD8, and CD25 in metastatic liver tissue on day 5,
10, 15 and 20 after intraportal injection of 1 × 105 CT26.WT cells (each group n = 7). Analysis was measured to control tissue (liver). (b)
Immunohistochemistry: Increasing number (in %) of CD4, Foxp3, CD8, and CD25 at metastatic sites in the liver over time (day 5, 10, 15 and 20)
after intraportal injection of 1 × 105 CT26.WT cells (each group n = 7). Lines with asterisks show significant increase during metastatic growth.
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Figure 2 (a) Immunohistochemistry and (b) immunofluorescence double staining: Representative image of CD4 (red)/CD8 (blue) (top)
expression and Foxp3 (FITC)/CD4 (Cy3) (bottom) expression in liver metastases on day 10 (n = 7) compared to increased CD4 (red)/
CD8 (blue) expression and Foxp3 (FITC)/CD4 (Cy3) expression on day 20. Immunohistochemistry: Nova red brick red color, Vector Blue blue
color. Haemalaun blue color-nuclear counterstaining. Asterisk with indication lines show metastases next to normal tissue (×100 and ×400).
Immunofluorescence: FITC green fluorescein isothiocyanate, Cy3 red and DAPI 4’,6-diamidino-2-phenylindole blue - nuclear counterstaining
(×250).
Figure 3 Real Time PCR: Significantly increasing gene expression of IL-10, TGF-b, TNF-a but a decrease of IFN-g at metastatic sites in
the liver on day 10, 15 and 20 after intraportal injection of 1 × 105 CT26.WT cells. Analysis was measured to control tissue (liver). Lines
with asterisks show significant differences during metastatic growth.
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compared to the situation in humans, reproduced prop-
erly by an animal model. Thus, the main purpose of
such a model should be to approximate as much charac-
teristics as possible of the emergence of liver metastases.
We are fully aware of the fact that our model does not
represent the initial steps of dissociation, invasion and
intravasation of the metastatic process [23]. Nonetheless,
taking into account the prompt and reproducible initia-
tion of a constant number of liver metastases following
intraportal injection of CT26.WT colon cancer cells, the
herein described model fulfils the demands of a
sufficient and biological reliable animal model requested
for the study of new therapeutical approaches.
The cellular invasion with predominantly lymphocytes
infiltrating the tumor is one of the main features of the
host immune response. The presence of tumor specific
T cells has been correlated with improved clinical out-
come in different human cancers [24,25], but does not
necessarily result in anti-tumor immunity since T cells
can also promote the progression of tumors through dif-
ferent growth factors [26]. In this regard high densities
of CD3+ tumor infiltrating T cells in node negative
Figure 4 (a) Real Time PCR: Downregulation of FAS gene expression from day 10 on following an initial increase but steadily
increasing of FAS-L gene expression in metastatic liver over time (day 5, 10, 15 and 20) following intraportal injection of 1 × 105
CT26.WT cells. Analysis was measured to control tissue (liver). (b) Immunohistochemistry: Increasing number (in %) of FAS-L expressing tumor
cells but a decreased FAS expression from day 10 on following intraportal injection of 1 × 105 CT26.WT cells.
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colorectal cancer were shown to make the occurrence of
metachrone metastases unlikely [27]. Furthermore, high
densities of CD8+/granzymeB+ T cells and CD45+
memory T cells at the tumor margin and in the center
of colorectal cancers were found to be a better predictor
of patient survival than the histopathological methods
usually used, leading to the hypothesis that not only the
type but also density and location of tumor infiltrating
T cells may be a more critical determinant for the
prognosis [28,29]. In this study we observed a steadily
increasing number of CD4+ and CD8+ T cells belea-
guering the liver metastases. In contrast to human colon
cancer in which the rate of tumor infiltrating lympho-
cytes is less than 10% of surrounding stromal cells [30],
we found a much higher number of primarily CD4+ T
cells. This has to be attributed to an obviously different
cellular immune response in this rodent model as the
quantity of tumor infiltrating lymphocytes seen in this
Figure 5 (a) Immunohistochemistry: Representative images of FAS-L expression in liver metastases on day 10 (left) compared to
increased FAS-L expression on day 20 (right). (b) Expression of FAS in liver metastasis on day 10 compared to day 20 demonstrating a
decreased expression in the course of metastatic growth. DAB (3,3’-diaminobenzidine) brown color, Haemalaun blue color - nuclear
counterstaining. Magnification ×100 and ×400. Case demonstrates area of magnification.
Figure 6 Immunofluorescence: Representative images of increased CD8+/FAS (a) and CD8+/TUNEL (b) expression on tumor infiltrating
lymphocytes at the margin of liver metastases on day 20. FITC green Fluoresceinisothiocyanat, Cy3 red and DAPI 4’,6-Diamidino-2-
phenylindoldihydrochlorid blue - nuclear countersaining. Case demonstrates area of the TUNEL staining in serial cryostat sections. To adjust a
better contrast TUNEL stained sections were not counterstained with DAPI. Asterisk with indication line shows metastatic tumor cells.
Magnifications ×250 (top) and ×400 (bottom).
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study obviously does not reflect the human situation.
The fact that most CD4+ T cells were also positive for
Foxp3 shows that at different points of time during car-
cinogenesis in this model, an increasing number of phe-
notypical regulatory T cells (Tregs) were detectable at
the tumor site demonstrating a potential protumoral
effect. This is in accordance with data showing that nat-
ural CD4+CD25+ Tregs may play a critical role in the
progression of a number of cancers by suppressing anti
tumor immune response effects [31-33]. In this regard
we previously demonstrated that an increasing number
of Tregs specific genes at the tumor site correlate with
the UICC stage of human colon cancer supporting the
protumoral effect of Tregs [10]. By contrast, however, it
was shown recently that a high density of Foxp3+ Tregs
in tumor tissue of patients with colon cancer was asso-
ciated with an improved survival [34]. Thus, the final
assessment of a potential anti- or protumoral effect of
Tregs in colon cancer can still not be served. Recently a
new CD8+CD25+Foxp3+ (T8reg) T cell subset was
described in patients with colon cancer [35]. Although
in small absolute number, T8regs were more abundant
in the blood and tumor tissue of tumor patients com-
pared to healthy volunteers. The study provides indirect
evidence for an inhibitory effect of T8regs on the antitu-
mor immune response which seems to be similar to the
effects mediated by CD4+CD25+ Tregs. In our study we
did not analyze the presence of T8regs which however
should be of interest in further studies.
CD4+ T cell response for anti-tumor immunity can be
divided into different types depending upon their cyto-
kine profile [36]. Th1 cells are characterized especially
by the production of IFN-g, whereas Th2, Th3 and Tr1
cells secret cytokines IL-4, IL-5, IL-10 and TGF-b. The
balance between Th1 and Th2/Th3/Tr1 cytokines has
definite influence on the outcome of various immune
responses, as Th1 preferentially induces cellular immu-
nity whereas the others tend to elicit humoral immunity.
Basically a Th1 cytokine profile mediates an anti-tumor
immunity whereas a Th2/Th3/Tr1 cytokine profile sup-
ports a pro-tumor activity. The change from a Th1 pro-
file to a Th2/Th3/Tr1 profile, the so called Th1-/Th2-
shift, is an important feature of an insufficient cellular
immunity during carcinogenesis [37,38]. In colon cancer
the expression of Th1-associated genes like IFN-g,
which exerts antiproliferative, antiangiogenic, and proa-
poptotic effects on a variety of tumor cells [39,40], was
significantly associated with a more favourable clinical
course of the disease [41].
In our tumor animal model described in this study
cytokines IL-10 and TGF-b were expressed increasingly
during carcinogenesis at different points of time in
metastatic liver tissue following intraportal CT26.WT
colon carcinoma cell injection whereas the expression of
IFN-g decreased beginning from day 10 after tumor cell
injection. These results are in accordance to previous
studies [4] and reflect the above mentioned Th1-/Th2
shift which could be observed in our model in the later
stages of carcinogenesis (day 10 to 20). TNF-a, which is
an important proinflammatory cytokine produced
mainly by macrophages and dendritic cells, is known to
support the development of IL-10 producing Tr1 cells
[42]. Thereby the protumoral cytokine profile is aug-
mented additionally by increasing levels of TNF-a,
which also has been demonstrated in a murine mela-
noma model [43]. Thus, in this model the pathophysio-
logical change of cytokine profiles seen in human reality
seems to be imitated properly.
It has been shown that the interaction between FAS
and its ligand (FAS-L) induced FAS-positive cell apopto-
sis in colorectal tumor cell lines [44]. Different strategies
of tumors to escape cancer immunosurveillance invol-
ving these molecules have been studied and led to the
so called “counterattack” hypothesis [45,46]. We
observed that FAS gene expression was down regulated
in liver metastases beginning from day 10 after tumor
cell injection following an initially increased expression.
FAS-L expression was increasingly detected at all points
of time during carcinogenesis. In addition, FAS-L
expression was clearly attributed to the tumor cell sur-
face in liver metastases shown by immunohistochemis-
try, while FAS expression was observed predominantly
on CD8+ T cells infiltrating the perimetastatic site.
Proper to this end the number of apoptotic CD8+ T
cells was increased time-dependent during growth of
metastases. This might contribute to the impairment of
the cellular anti-tumor immune response although ele-
vated gene expression and immunohistological confir-
mation of an increasing number of CD8+ T cells was
demonstrated during carcinogenesis in our model. This
result supports the “counterattack” hypothesis morpho-
logically and implies that tumor cells possibly circum-
vent immunological surveillance by up-regulation of
FAS-L expression and down-regulation of FAS, at least
at later stages of carcinogenesis. The “counterattack”
hypothesis, however, is hard to prove in vivo, since we
cannot demonstrate the functional significance of these
findings by mere morphological observation.
Conclusion
In conclusion, this study describes immunological
escape mechanisms during metastatic tumor growth in a
colorectal liver metastases mouse model at different
points in time. We have shown that tumor growth
induced an extensive cellular immune response of pre-
dominantly regulatory T cells with a presumably protu-
moral activity. Furthermore we could demonstrate a
shift from Th1- to Th2-associated cytokine profiles
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during carcinogenesis simulating the situation in human
cancer. Additionally a further feature of tumor immune
escape mechanisms, the FAS/FAS-L “counterattack”,
could be shown in the described murine model.
Taken together this model simulates several features
of immunological escape mechanisms during carcino-
genesis and might serve as a model for immunothera-
peutic intervention studies.
Acknowledgements
This work was supported by The Deutsche Bundesstiftung Umwelt (DBU,
16011). The authors thank the assistance of Mrs. Ulrike Faber in the
preparation of this manuscript, and Mrs. Andrea Trumpfheller, Mrs. Sabine
Mueller, and Mrs. Mariola Dragan for their technical support.
Author details
1Department of General Surgery, University of Wuerzburg Hospital, Germany.
2Department of General Surgery, Molecular Oncology and Immunology,
University of Wuerzburg Hospital, Germany. 3Department of General Surgery,
Leopoldina Hospital, Schweinfurt, Germany.
Authors’ contributions
MG was responsible for immunohistochemical analysis and drafting of the
manuscript. MG and MB participated in the surgical animal procedures and
the surveillance of operated mice. JS, JW and EN assisted in surgical animal
procedures, performed the RT-PCR experiments and participated in data
analysis. DM was involved in establishing microsurgical techniques. CTG and
AMWG participated in the design of the study and its coordination. AT was
responsible for the interpretation of all data and drafting of the manuscript.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 3 July 2009
Accepted: 7 March 2010 Published: 7 March 2010
References
1. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR,
Hammond ME, Henson DE, Hutter RV, Nagle RB, Nielsen ML, Sargent DJ,
Taylor CR, Welton M, Willett C: Prognostic Factors in Colorectal Cancer.
College of American Pathologists Consensus Statement 1999. Arch Pathol
Lab Med 2000, 7:979-994.
2. Scheele J, Stangl R, Altendorf-Hofmann A: Hepatic Metastases From
Colorectal Carcinoma: Impact of Surgical Resection on the Natural
History. Br J Surg 1990, 11:1241-1246.
3. Lorenz M, Staib-Sebler E, Hochmuth K, Heinrich S, Gog C, Vetter G, Encke A,
Muller HH: Surgical Resection of Liver Metastases of Colorectal
Carcinoma: Short and Long-Term Results. Semin Oncol 2000, 5(Suppl
10):112-119.
4. Jarnicki AG, Lysaght J, Todryk S, Mills KH: Suppression of Antitumor
Immunity by IL-10 and TGF-Beta-Producing T Cells Infiltrating the
Growing Tumor: Influence of Tumor Environment on the Induction of
CD4+ and CD8+ Regulatory T Cells. J Immunol 2006, 2:896-904.
5. Elkord E, Hawkins RE, Stern PL: Immunotherapy for Gastrointestinal
Cancer: Current Status and Strategies for Improving Efficacy. Expert Opin
Biol Ther 2008, 4:385-395.
6. Khong HT, Restifo NP: Natural Selection of Tumor Variants in the
Generation of “Tumor Escape” Phenotypes. Nat Immunol 2002,
11:999-1005.
7. Kosmaczewska A, Ciszak L, Potoczek S, Frydecka I: The Significance of Treg
Cells in Defective Tumor Immunity. Arch Immunol Ther Exp (Warsz) 2008,
3:181-191.
8. Oldenhove G, de Heusch M, Urbain-Vansanten G, Urbain J, Maliszewski C,
Leo O, Moser M: CD4+ CD25+ Regulatory T Cells Control T Helper Cell
Type 1 Responses to Foreign Antigens Induced by Mature Dendritic
Cells in Vivo. J Exp Med 2003, 2:259-266.
9. Cui G, Florholmen J: Polarization of Cytokine Profile From Th1 into Th2
Along Colorectal Adenoma-Carcinoma Sequence: Implications for the
Biotherapeutic Target?. Inflamm Allergy Drug Targets 2008, 2:94-97.
10. Bueter M, Gasser M, Schramm N, Lebedeva T, Tocco G, Gerstlauer C,
Grimm M, Nichiporuk E, Thalheimer A, Thiede A, Meyer D, Benichou G,
Waaga-Gasser AM: T-Cell Response to P53 Tumor-Associated Antigen in
Patients With Colorectal Carcinoma. Int J Oncol 2006, 2:431-438.
11. Golgher D, Jones E, Powrie F, Elliott T, Gallimore A: Depletion of CD25+
Regulatory Cells Uncovers Immune Responses to Shared Murine Tumor
Rejection Antigens. Eur J Immunol 2002, 11:3267-3275.
12. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC,
Kaiser LR, June CH: Regulatory CD4(+)CD25(+) T Cells in Tumors From
Patients With Early-Stage Non-Small Cell Lung Cancer and Late-Stage
Ovarian Cancer. Cancer Res 2001, 12:4766-4772.
13. Sakaguchi S: Regulatory T Cells: Key Controllers of Immunologic Self-
Tolerance. Cell 2000, 5:455-458.
14. Mills KH: Regulatory T Cells: Friend or Foe in Immunity to Infection?. Nat
Rev Immunol 2004, 11:841-855.
15. Hisaeda H, Maekawa Y, Iwakawa D, Okada H, Himeno K, Kishihara K,
Tsukumo S, Yasutomo K: Escape of Malaria Parasites From Host Immunity
Requires CD4+ CD25+ Regulatory T Cells. Nat Med 2004, 1:29-30.
16. Yu P, Fu YX: Tumor-Infiltrating T Lymphocytes: Friends or Foes?. Lab
Invest 2006, 3:231-245.
17. Jakowlew SB: Transforming Growth Factor-Beta in Cancer and Metastasis.
Cancer Metastasis Rev 2006, 3:435-457.
18. Kollmar O, Schilling MK, Menger MD: Experimental Liver Metastasis:
Standards for Local Cell Implantation to Study Isolated Tumor Growth in
Mice. Clin Exp Metastasis 2004, 5:453-460.
19. Thalheimer A, Otto C, Bueter M, Illert B, Gattenlohner S, Gasser M, Meyer D,
Fein M, Germer CT, Waaga-Gasser AM: The Intraportal Injection Model: a
Practical Animal Model for Hepatic Metastases and Tumor Cell
Dissemination in Human Colon Cancer. BMC Cancer 2009, 29.
20. Burnet M: Cancer: a Biological Approach. III. Viruses Associated With
Neoplastic Conditions. IV. Practical Applications. Br Med J 1957,
5023:841-847.
21. Chan WS, Page CM, Maclellan JR, Turner GA: The Growth and Metastasis
of Four Commonly Used Tumour Lines Implanted into Eight Different
Sites: Evidence for Site and Tumour Effects. Clin Exp Metastasis 1988,
3:233-244.
22. Isbert C, Boerner A, Ritz JP, Schuppan D, Buhr HJ, Germer CT: In Situ
Ablation of Experimental Liver Metastases Delays and Reduces Residual
Intrahepatic Tumour Growth and Peritoneal Tumour Spread Compared
With Hepatic Resection. Br J Surg 2002, 10:1252-1259.
23. Chambers AF, Groom AC, MacDonald IC: Dissemination and Growth of
Cancer Cells in Metastatic Sites. Nat Rev Cancer 2002, 8:563-572.
24. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M,
Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC,
Coukos G: Intratumoral T Cells, Recurrence, and Survival in Epithelial
Ovarian Cancer. N Engl J Med 2003, 3:203-213.
25. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE,
Davis MM: Evidence That Specific T Lymphocytes May Participate in the
Elimination of Chronic Myelogenous Leukemia. Nat Med 2000,
9:1018-1023.
26. Inagaki A, Ishida T, Ishii T, Komatsu H, Iida S, Ding J, Yonekura K, Takeuchi S,
Takatsuka Y, Utsunomiya A, Ueda R: Clinical Significance of Serum Th1-,
Th2- and Regulatory T Cells-Associated Cytokines in Adult T-Cell
Leukemia/Lymphoma: High Interleukin-5 and -10 Levels Are Significant
Unfavorable Prognostic Factors. Int J Cancer 2006, 12:3054-3061.
27. Laghi L, Bianchi P, Miranda E, Balladore E, Pacetti V, Grizzi F, Allavena P,
Torri V, Repici A, Santoro A, Mantovani A, Roncalli M, Malesci A: CD3+ Cells
at the Invasive Margin of Deeply Invading (PT3-T4) Colorectal Cancer
and Risk of Post-Surgical Metastasis: a Longitudinal Study. Lancet Oncol
2009, 9:877-884.
28. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-
Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I,
Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L,
Zou W: Specific Recruitment of Regulatory T Cells in Ovarian Carcinoma
Fosters Immune Privilege and Predicts Reduced Survival. Nat Med 2004,
9:942-949.
29. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C,
Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P,
Grimm et al. BMC Cancer 2010, 10:82
http://www.biomedcentral.com/1471-2407/10/82
Page 10 of 11
Cugnenc PH, Trajanoski Z, Fridman WH, Pages F: Type, Density, and
Location of Immune Cells Within Human Colorectal Tumors Predict
Clinical Outcome. Science 2006, 5795:1960-1964.
30. Michael-Robinson JM, Pandeya N, Walsh MD, Biemer-Huttmann AE, Eri RD,
Buttenshaw RL, Lincoln D, Clouston AD, Jass JR, Radford-Smith GL:
Characterization of Tumour-Infiltrating Lymphocytes and Apoptosis in
Colitis-Associated Neoplasia: Comparison With Sporadic Colorectal
Cancer. J Pathol 2006, 3:381-387.
31. Clarke SL, Betts GJ, Plant A, Wright KL, El Shanawany TM, Harrop R,
Torkington J, Rees BI, Williams GT, Gallimore AM, Godkin AJ: CD4+CD25
+FOXP3+ Regulatory T Cells Suppress Anti-Tumor Immune Responses in
Patients With Colorectal Cancer. PLoS One 2006, e129.
32. Loddenkemper C, Schernus M, Noutsias M, Stein H, Thiel E, Nagorsen D: In
Situ Analysis of FOXP3+ Regulatory T Cells in Human Colorectal Cancer.
J Transl Med 2006, 52.
33. Casares N, Arribillaga L, Sarobe P, Dotor J, Lopez-Diaz dC, Melero I, Prieto J,
Borras-Cuesta F, Lasarte JJ: CD4+/CD25+ Regulatory Cells Inhibit
Activation of Tumor-Primed CD4+ T Cells With IFN-Gamma-Dependent
Antiangiogenic Activity, As Well As Long-Lasting Tumor Immunity
Elicited by Peptide Vaccination. J Immunol 2003, 11:5931-5939.
34. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C,
Iacopetta B: Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong
Prognostic Significance in Colorectal Cancer. J Clin Oncol 2009, 2:186-192.
35. Chaput N, Louafi S, Bardier A, Charlotte F, Vaillant JC, Menegaux F,
Rosenzwajg M, Lemoine F, Klatzmann D, Taieb J: Identification of CD8
+CD25+Foxp3+ Suppressive T Cells in Colorectal Cancer Tissue. Gut
2009, 4:520-529.
36. Mosmann TR, Sad S: The Expanding Universe of T-Cell Subsets: Th1, Th2
and More. Immunol Today 1996, 3:138-146.
37. Romagnani S: The Th1/Th2 Paradigm. Immunol Today 1997, 6:263-266.
38. Cui G, Florholmen J: Polarization of Cytokine Profile From Th1 into Th2
Along Colorectal Adenoma-Carcinoma Sequence: Implications for the
Biotherapeutic Target?. Inflamm Allergy Drug Targets 2008, 2:94-97.
39. Beatty G, Paterson Y: IFN-Gamma-Dependent Inhibition of Tumor
Angiogenesis by Tumor-Infiltrating CD4+ T Cells Requires Tumor
Responsiveness to IFN-Gamma. J Immunol 2001, 4:2276-2282.
40. Ikeda H, Old LJ, Schreiber RD: The Roles of IFN Gamma in Protection
Against Tumor Development and Cancer Immunoediting. Cytokine
Growth Factor Rev 2002, 2:95-109.
41. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R,
Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P,
Cugnenc PH, Trajanoski Z, Fridman WH, Galon J: Effector Memory T Cells,
Early Metastasis, and Survival in Colorectal Cancer. N Engl J Med 2005,
25:2654-2666.
42. Hirata N, Yanagawa Y, Satoh M, Ogura H, Ebihara T, Noguchi M,
Matsumoto M, Togashi H, Seya T, Onoe K, Iwabuchi K: Dendritic Cell-
Derived TNF-Alpha Is Responsible for Development of IL-10-Producing
CD4+ T Cells. Cell Immunol 2010, 1:37-41.
43. Vohra N, Verhaegen M, Martin L, Mackay A, Pilon-Thomas S: TNF-Alpha-
Treated DC Exacerbates Disease in a Murine Tumor Metastasis Model.
Cancer Immunol Immunother 2009.
44. Radfar S, Martin H, Tilkin-Mariame AF: [Tumor Escape Mechanism
Involving Fas and Fas-L Molecules in Human Colorectal Tumors].
Gastroenterol Clin Biol 2000, 12:1191-1196.
45. Ryan AE, Shanahan F, O’Connell J, Houston AM: Fas Ligand Promotes
Tumor Immune Evasion of Colon Cancer in Vivo. Cell Cycle 2006,
3:246-249.
46. Sheehan KM, O’Donovan DG, Fitzmaurice G, O’Grady A, O’Donoghue DP,
Sheahan K, Byrne MF, Conroy RM, Kay EW, Murray FE: Prognostic
Relevance of Fas (APO-1/CD95) Ligand in Human Colorectal Cancer. Eur
J Gastroenterol Hepatol 2003, 4:375-380.
Pre-publication history
The pre-publication history for this paper can be accessed here:http://www.
biomedcentral.com/1471-2407/10/82/prepub
doi:10.1186/1471-2407-10-82
Cite this article as: Grimm et al.: Evaluation of immunological escape
mechanisms in a mouse model of colorectal liver metastases. BMC
Cancer 2010 10:82.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Grimm et al. BMC Cancer 2010, 10:82
http://www.biomedcentral.com/1471-2407/10/82
Page 11 of 11
